Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status
Cancer Science · 2023
DOI: 10.1111/cas.15813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Reika Takamatsu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cell Science Research Foundation, JSPS KAKENHI, Kanzawa Medical Research Foundation.
Abstract (Originalsprache)
The microsatellite instability (MSI)/mismatch repair (MMR) status is one of the critical genomic biomarkers for predicting patient response to immune checkpoint inhibitors (ICIs). In this study, we aimed to investigate the concordance among the MSIsensor score obtained from whole‐exome sequencing (WES), which could be a futuristic clinical cancer sequencing method, using only tumor tissues, MSI‐PCR results, and immunohistochemistry (IHC) results to analyze various solid cancer types. We first endeavored to set the cut‐off value of MSIsensor to determine functional deficient mismatch repair (f‐dMMR) status. The MSI status of 1054 patients analyzed using WES was evaluated using MSIsensor. In addition, 87 of these patients were further analyzed using MSI‐PCR and MMR IHC to calculate the sensitivity and specificity of the MSIsensor cut‐off score. Our results showed that score 12.5 was an adequate cut‐off score equivalent to PCR‐confirmed MSS/MSI‐low and MSI‐high statuses, with sensitivity, specificity, and area under the curve values of 95.2%, 100%, and 0.998, respectively. Moreover, we identified false‐positive cases of tumors with high mutational burden with an MSIsensor score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Kumagaya General Hospital, Kumagaya, Japan.
- Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Department of Biomedical Informatics, Communication Engineering Center, Electronic Systems Business Group, Mitsubishi Electric Software Co., Ltd, Amagasaki, Japan.
- Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Kohei Nakamura, Hideyuki Hayashi, Hiroshi Nishihara
Förderung
- Cell Science Research Foundation
- JSPS KAKENHI
- Kanzawa Medical Research Foundation
- Takeda Science Foundation
- Uehara Memorial Foundation
Zitieren
APA
Takamatsu, R., Nakamura, K., Suzuki, O., Okada, C., Mori, R., Kawano, R., Hayashi, H., Ishikawa, M., Aimono, E., Nohara, S., Tanishima, S., Ueki, A., Ishida, H., & Nishihara, H. (2023). Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status. Cancer Science. https://doi.org/10.1111/cas.15813
Vancouver
Takamatsu R, Nakamura K, Suzuki O, Okada C, Mori R, Kawano R, et al. Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status. Cancer Science. 2023. doi:10.1111/cas.15813
BibTeX
@article{Takamatsu2023,
author = {Takamatsu, Reika and Nakamura, Kohei and Suzuki, Okihide and Okada, Chihiro and Mori, Ryo and Kawano, Ryutaro and Hayashi, Hideyuki and Ishikawa, Marin and Aimono, Eriko and Nohara, Sachio and Tanishima, Shigeki and Ueki, Arisa and Ishida, Hideyuki and Nishihara, Hiroshi},
title = {Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15813}
}
EUVIMED